Micofenolato De Mofetil Aurovitas

Mycophenolate Mofetil, the active ingredient in Micofenolato De Mofetil Aurovitas, is an immunosuppressant presented as an oral tablet for oral use. It is employed to prevent organ transplant rejection and to treat autoimmune conditions such as lupus nephritis, helping to control immune‑mediated damage.

GNH USA supplies Micofenolato De Mofetil Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil is an antimetabolite immunosuppressant used in transplant and autoimmune disease management.

Kidney transplant: reduces the risk of acute graft rejection. Liver transplant: supports long‑term graft survival. Lupus nephritis: helps control renal inflammation and preserve kidney function.

Mycophenolate Mofetil may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Gastrointestinal upset: nausea, vomiting, diarrhea. - Hematologic changes: anemia, leukopenia, thrombocytopenia. - Infections: increased susceptibility to bacterial, viral and fungal infections. - Headache and fatigue. - Elevated liver enzymes.

Serious or Rare Side Effects: - Severe neutropenia or agranulocytosis. - Opportunistic infections such as Pneumocystis jirovecii pneumonia. - Progressive multifocal leukoencephalopathy (PML). - Hepatotoxicity with jaundice. - Malignancies, particularly lymphoproliferative disorders. - Reproductive toxicity leading to fetal harm.

When prescribing Mycophenolate Mofetil, clinicians should consider several safety measures.

Monitor blood counts: regular CBC to detect cytopenias. Assess renal function: dose may need adjustment in renal impairment. Screen for infections: evaluate for latent TB and viral hepatitis before initiation. Avoid live vaccines: patients on therapy have reduced immune defenses. Pregnancy warning: drug is contraindicated in pregnancy due to teratogenic risk. Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Mycophenolate Mofetil interacts with several medicines that can alter its exposure or increase toxicity.

Major Interactions (Avoid): - Antacids containing magnesium or aluminum: reduce absorption of the drug. - Azathioprine: additive bone‑marrow suppression. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly lower mycophenolate levels.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may enhance renal effects. - Trimethoprim‑sulfamethoxazole: increased risk of myelosuppression. - Vaccines: live attenuated vaccines should be avoided during therapy.